Acquired thrombophilias and pregnancy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 3, 2003, Pages 491-507

  Khare, Manjiri ^b   Nelson Piercy, Catherine ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Aspirin; Low molecular weight heparin; Lupus anticoagulant; Recurrent miscarriage; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; COUMARIN; CYTOKINE; DALTEPARIN; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; STEROID; VITAMIN K GROUP; WARFARIN;

ACQUIRED THROMBOPHILIA; ANTIPHOSPHOLIPID SYNDROME; BIRTH RATE; BREAST FEEDING; CENTRAL NERVOUS SYSTEM MALFORMATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; FETUS WASTAGE; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INTERNATIONAL COOPERATION; LABORATORY DIAGNOSIS; LOW DRUG DOSE; MATERNAL DIABETES MELLITUS; META ANALYSIS; MONOTHERAPY; OBSTETRICS; OSTEOPOROSIS; PATHOGENESIS; PATIENT COUNSELING; PHYSICAL DISABILITY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; RECURRENT ABORTION; REVIEW; RISK; SEPSIS; SIDE EFFECT; STANDARDIZATION; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TREATMENT PLANNING;

EID: 0038380475     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00013-0     Document Type: Review

References (89)

1. Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Services Northern Ireland. Confidential Enquiries into Maternal Deaths in the United Kingdom 1997-1999. London: HMSO. 2001.
2. Roubey RA. Antigenic specificities of antiphospholipid autoantibodies: Implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome. Lupus 1996;5:425-430.
3. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
4. McNeil HP, Hunt JE & Krilis SA. New aspects of anticardiolipin antibodies. Clinical and Experimental Rheumatology 1990; 8: 525-527.
5. Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178.
6. Pattison NS, Birdsall M, Chanley LW & Lubbe WF. Recurrent fetal loss and the antiphospholipid syndrome. Recent Advances in Obstetrics and Gynaecology 1994; 18: 23-50.
7. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Journal of Autoimmunity 2000; 15: 145-151.
8. Lockwood CJ, Romero R, Feinberg RF et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. American Journal of Obstetrics and Gynecology 1989; 161: 369-373.
9. Perez MC, Wilson WA, Brown HL & Scopelitis E. Anticardiolipin antibodies in unselected pregnant women. Relationship to fetal outcome. Journal of Perinatology 1991; 11: 33-36.
10. Harris EN & Spinnato JA. Should cardiolipin tests be performed on otherwise healthy pregnant women? American Journal of Obstetrics and Gynecology 1992; 165: 1272-1277.
11. Greaves M, Cohen H, Machin SJ & Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology 2000; 109: 704-715.
12. Pierangeli SS, Gharavi AE & Harris EN. Testing for antiphospholipid antibodies: Problems and solutions. Clinical Obstetrics and Gynecology 2001; 44: 48-57.
13. Gharavi AE, Harris EN, Asherson RA & Hughes GR. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Annals of the Rheumatic Diseases 1987; 46: 1-6.
14. Martinuzzo ME, Forastiero RR & Carreras LO. Anti beta 2 glycoprotein I antibodies: Detection and association with thrombosis. British Journal of Haematology 1995; 89: 397-402.
15. Guerin J, Feighery C, Sim RB & Jackson J. Antibodies to β2-glycoprotein I - A specific marker for the antiphospholipid syndrome. Clinical and Experimental Immunology 1997; 109: 304-309.
16. Pierangeli SS, Gharavi AE & Harris EN. Testing for antiphospholipid antibodies: Problems and solutions. Clinical Obstetrics and Gynecology 2001; 44: 48-57.
17. Protein Reference Unit - Handbook of Clinical Immunocytochemistry. Sheffield PRU Publications, 2000.
18. Kwak JY, Barini R, Gilman-Sachs A et al. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. American Journal of Obstetrics and Gynecology 1994; 171: 239-246.
19. Stone S, Langford K, Nelson-Piercy C et al. Antiphospholipid antibodies do not a syndrome make. Lupus 2002; 11: 130-133.
20. Ichikawa K, Khamashta MA, Koike T et al. Beta 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis and Rheumatism 1994; 37: 1453-1461.
21. Di Simone N, Meroni PL, De Papa N et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis and Rheumatism 2000; 43: 140-150.
22. Chamley LW, Duncalf AM, Mitchell MD & Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352: 1037-1038.
23. Stone S, Khamashta MA & Poston L. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus 2001; 10: 67-74.
24. Gastineau DA, Kazmier FJ, Nichols WL & Bowie EJ. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. American Journal of Hematology 1985; 19: 265-275.
25. Lechner K & Pabinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 1985; 15: 254-262.
26. Khamashta MA, Cuadrado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. New England Journal of Medicine 1995; 332: 993-997.
27. Hart R, Miller V & Coull B. Cerebral infarctions associated with lupus anticoagulants. Stroke 1987; 18: 257-263.
28. Nzereu CM, Hewan-Lowe K, Pierangei S & Harris EN. 'Black swan in the kidney': Renal involvement in the antiphospholipid antibody syndrome. Kidney International 2002; 62: 733-744.
29. Branch DW. Antiphospholipid antibodies and pregnancy: Maternal implications. Seminars in Perinatology 1990; 14: 139-146.
30. Lima F, Khamashta MA, Buchanan NM et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clinical and Experimental Rheumatology 1996; 14: 131-136.
31. Ringrose D. Anaesthesia and antiphospholipid syndrome - A review of 20 obstetric patients. International Journal of Obstetric Anesthesia 1997; 6: 107-111.
32. Lockshin MD, Druzin ML, Goei S et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. New England Journal of Medicine 1985; 313: 152-156.
33. Oshiro BT, Silver RM, Scott JR et al. Antiphospholipid antibodies and fetal death. Obstetrics and Gynecology 1996; 87: 489-493.
34. Levine JS, Branch DW & Rauch J. The antiphospholipid syndrome. New England Journal of Medicine 2002; 346: 752-763.
35. MacLean MA, Cumming GP, McCall F et al. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. British Journal of Obstetrics and Gynaecology 1994; 101: 103-106.
36. Silver RM & Branch DW. Recurrent miscarriage: Autoimmune considerations. Clinical Obstetrics and Gynecology 1994; 37: 745-760.
37. Rai RS, Regan L, Clifford K et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: Results of a comprehensive screening approach. Human Reproduction 1995; 10: 2001-2005.
38. Out HJ, Kooijiman CD, Bruinse HW & Derksen RH. Histopathological findings in placentae from patients with intrauterine fetal death and anti-phospholipid antibodies. European Journal of Obstetrics, Gynecology and Reproductive Biology 1991; 41: 179-186.
39. Sebire NJ, Backos M, Goldin RD & Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. British Journal of Obstetrics and Gynaecology 2002; 109: 570-573.
40. De Wolf F, Carreras LO, Moerman P et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. American Journal of Obstetrics and Gynecology 1982; 142: 829-834.
41. Abramowsky CR, Vegas ME, Swinehart G & Gyves MT. Decidual vasculopathy of the placenta in lupus erythematosus. New England Journal of Medicine 1980; 303: 668-672.
42. Girling J & De Swiet M. Acquired thrombophilia. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 447-462.
43. Chappell LC, Seed PT, Briley AL et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial. Lancet 1999; 354: 810-816.
44. Chien PF, Arnott N, Gordon A et al. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. British Journal of Obstetrics and Gynaecology 2000; 107: 196-208.
45. Lees C, Parra M, Missfelder-Lobos H et al. Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks. Obstetrics and Gynecology 2001; 98: 369-373.
46. Papageorghiou AT, Yu CK, Bindra R et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound in Obstetrics and Gynecology 2001; 18: 441-449.
47. Branch DW, Dudley DJ, Scott JR & Silver RM. Antiphospholipid antibodies and fetal loss. New England Journal of Medicine 1992; 326: 952-954.
48. Roubey RA. Treatment of the antiphospholipid syndrome. Current Opinion in Rheumatology 2002; 14: 238-242.
49. Lockshin MD, Druzin ML & Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. American Journal of Obstetrics and Gynecology 1989; 160: 439-443.
50. Silver RM, Pierangeli SS, Gharavi AE et al. Induction of high levels of anticardiolipin antibodies in mice by immunisation with beta 2-glycoprotein I does not cause fetal death. American Journal of Obstetrics and Gynecology 1995; 173: 1410-1415.
51. Cowchock FS, Reece EA, Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomised trial comparing prednisolone with low-dose heparin treatment. American Journal of Obstetrics and Gynecology 1992; 166: 1318-1323.
52. Shoenfeld Y, Blank M & Sherer Y. Induction and treatment of the antiphospholipid syndrome - Lessons from animal models. European Journal of Clinical Investigation 2001; 31: 736-740.
53. Cowchock S & Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. American Journal of Obstetrics and Gynecology 1997; 176: 1099-1100.
54. Pattison NS, Chamley LW, Birdsall M et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial. American Journal of Obstetrics and Gynecology 2000; 183: 1008-1012.
55. Ruiz-Irastorza G, Nelson-Piercy C & Khamashta MA. Aspirin to treat obstetric manifestations of the antiphospholipid syndrome. American Journal of Obstetrics and Gynecology 2001; 185: 523-524.
56. Shehata HA, Nelson-Piercy C & Khamashta MA. Management of pregnancy in antiphospholipid syndrome. Rheumatic Disease Clinics of North America 2001; 27: 643-659.
57. Rosove MH, Tabsh K, Wasserstrum N et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstetrics and Gynecology 1990; 75: 630-634.
58. Ruffatti A, Orsini A, Di Lenardo L et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss. Clinical and Experimental Rheumatology 1997; 15: 499-505.
59. Lockshin MD. Which patients with antiphospholipid antibody should be treated and how? Rheumatic Diseases Clinics of North America 1993; 19: 235-247.
60. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. American Journal of Obstetrics and Gynecology 1993; 168: 1265-1270.
61. De Swiet M, Ward PD, Fidler J et al. Prolonged heparin therapy in pregnancy causes bone demineralisation. British Journal of Obstetrics and Gynaecology 1983; 90: 1129-1134.
62. Khastgir G & Studd J. Pregnancy-associated osteoporosis. British Journal of Obstetrics and Gynaecology 1994; 101: 836-838.
63. Nelson-Piercy C. Heparin-induced osteoporosis in pregnancy. Lupus 1997; 6: 500-504.
64. Smith R, Athanasou NA, Ostlere SJ & Vipond SE. Pregnancy-associated osteoporosis. Quarterly Journal of Medicine 1995; 88: 865-878.
65. Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thrombosis and Haemostasis 1999; 81: 668-672.
66. Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: A retrospective study of enoxaparin safety in 624 pregnancies. British Journal of Obstetrics and Gynaecology 2001; 108: 1134-1140.
67. Nelson-Piercy C. Thromboprophylaxis in pregnancy and after normal vaginal delivery. RCOG Clinical Green Top Guidelines 2003; (in press).
68. Nelson-Piercy C, Letsky EA & De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. American Journal of Obstetrics and Gynecology 1997; 176: 1062-1068.
69. Hall JG, Pauli RM & Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. American Journal of Medicine 1980; 68: 122-140.
70. Schardein JL. Chemically Induced Birth Defects, 2nd edn. New York: Marcel Dekker, 1993.
71. Stevenson RE, Burton OM, Ferlauto GJ & Taylor HA. Hazards of oral anticoagulants during pregnancy. Journal of the American Medical Association 1980; 243: 1549-1551.
72. Hunt BJ, Doughty HA, Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis and Haemostasis 1997; 77: 39-43.
73. Branch DW, Peaceman AM, Druzin M et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. American Journal of Obstetrics and Gynecology 2000; 182: 122-127.
74. Somerset DA, Raine-Fenning N, Gordon C et al. Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. European Journal of Obstetrics, Gynecology and Reproductive Biology 1998; 79: 227-229.
75. Fulcher D, Stewart G, Exner T et al. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet 1989; 11: 171.
76. Fishman P, Falach-Vaknine E, Zigelman R et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. Journal of Clinical Investigation 1993; 91: 1834-1837.
77. Jones DS, Cockerill KA, Gamino CA et al. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response. Bioconjugate Chemistry 2001; 12: 1012-1020.
78. Ames PR, Tommasino C, Alves J et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: A pilot study. Lupus 2000; 9: 688-695.
79. Orme ML, Lewis PJ & De Swiet M. May mothers given warfarin breast-feed their infants? British Medical Journal 1997; 11: 1564-1565.
80. McKenna R, Cole ER & Vasan U. Is warfarin sodium contraindicated in the lactating mother? Journal of Pediatrics 1983; 103: 325-327.
81. Esplin MS. Management of antiphospholipid syndrome during pregnancy. Clinical Obstetrics and Gynecology 2001; 44: 20-28.
82. Silver RM, Draper ML, Byrne JL et al. Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: A harbinger of fetal death. Obstetrics and Gynecology 1994; 83: 150-155.
83. Brandt JT, Barna LK & Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thrombosis and Haemostasis 1995; 74: 1597-1603.
84. Branch DW, Silver RM, Blackwell JL et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience. Obstetrics and Gynecology 1992; 80: 614-620.
85. Granger KA & Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6: 509-513.
86. Backos M, Rai R, Baxter N et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. British Journal of Obstetrics and Gynaecology 1999; 106: 102-107.
87. Rai R, Cohen H, Dave M & Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal 1997; 314: 253-257.
88. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology 1996; 174: 1584-1589.
89. Farquharson RG, Quenby S & Greaves M. Antiphospholipid syndrome in pregnancy: A controlled treatment trial. Journal of Obstetrics and Gynecology 2001; 21(supplement 1): S22.